litlas
ログインアカウント作成

Koji Tamada

1999–2025 年に発表

62
論文数
19,357
被引用数
50
h 指数
61
i10 指数

被引用数

Koji Tamada の年別被引用数1987 年: 被引用 1 件1994 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 13 件2001 年: 被引用 55 件2002 年: 被引用 96 件2003 年: 被引用 180 件2004 年: 被引用 194 件2005 年: 被引用 194 件2006 年: 被引用 195 件2007 年: 被引用 196 件2008 年: 被引用 226 件2009 年: 被引用 220 件2010 年: 被引用 172 件2011 年: 被引用 160 件2012 年: 被引用 163 件2013 年: 被引用 272 件2014 年: 被引用 273 件2015 年: 被引用 406 件2016 年: 被引用 376 件2017 年: 被引用 385 件2018 年: 被引用 297 件2019 年: 被引用 805 件2020 年: 被引用 819 件2021 年: 被引用 785 件2022 年: 被引用 584 件2023 年: 被引用 414 件2024 年: 被引用 605 件2025 年: 被引用 288 件2026 年: 被引用 10 件1988〜1993 年は被引用が無いため表示していません1995〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,695 件、この内訳の 31.8%中国: 引用元論文 1,667 件、この内訳の 19.7%日本: 引用元論文 430 件、この内訳の 5.1%ドイツ: 引用元論文 399 件、この内訳の 4.7%イギリス: 引用元論文 331 件、この内訳の 3.9%フランス: 引用元論文 269 件、この内訳の 3.2%イタリア: 引用元論文 253 件、この内訳の 3%スペイン: 引用元論文 197 件、この内訳の 2.3%カナダ: 引用元論文 180 件、この内訳の 2.1%韓国: 引用元論文 167 件、この内訳の 2%オーストラリア: 引用元論文 165 件、この内訳の 1.9%オランダ: 引用元論文 133 件、この内訳の 1.6%
0%31.8%その他 18.7%

機関

分野

  • Medicine63%
  • Immunology and Microbiology22.4%
  • Biochemistry, Genetics and Molecular Biology11.6%
  • Neuroscience1.1%
  • Engineering0.8%
  • Materials Science0.2%
  • その他0.9%

トピック

  • Cancer Immunotherapy and Biomarkers16.1%
  • Immunotherapy and Immune Responses11%
  • Immune Cell Function and Interaction10.3%
  • CAR-T cell therapy research9.7%
  • T-cell and B-cell Immunology3.8%
  • Immune cells in cancer3.1%
  • その他46%

共著者

全論文

検索で開く
  1. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

    著者: Haidong Dong, Scott E. Strome, Diva R. Salomão, Hideto Tamura, Fumiya Hirano, Dallas B. Flies, Patrick C. Roche, Jun Lü, Gefeng Zhu, Koji Tamada, Vanda A. Lennon, Esteban Celis, Lieping Chen - Nature Medicine 2002 被引用: 5,015

  2. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

    著者: Keishi Adachi, Yosuke Kano, Tomohiko Nagai, Namiko Okuyama, Yukimi Sakoda, Koji Tamada - Nature Biotechnology 2018 被引用: 772

  3. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

    著者: Haidong Dong, Gefeng Zhu, Koji Tamada, Lieping Chen - Nature Medicine 1999 被引用: 2,486

  4. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production

    著者: Andrei I. Chapoval, Jian Ni, Julie S. Lau, Ryan A. Wilcox, Dallas B. Flies, Ding Liu, Haidong Dong, Gabriel Sica, Gefeng Zhu, Koji Tamada, Lieping Chen - Nature Immunology 2001 被引用: 1,021

  5. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells

    著者: Tatsuki Ueda, Sara Shiina, Shoichi Iriguchi, Seitaro Terakura, Yohei Kawai, Ryotaro Kabai, Satoko Sakamoto, Akira Watanabe, Kohei Ohara, Bo Wang, Huaigeng Xu, Atsutaka Minagawa, Akitsu Hotta, Knut Woltjen, Yasushi Uemura, Yuzo Kodama, Hiroshi Seno, Tetsuya Nakatsura, Koji Tamada, Shin Kaneko - Nature Biomedical Engineering 2022 被引用: 60

  6. Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity

    著者: Fumiya Hirano, Katsumi Kaneko, Hideto Tamura, Haidong Dong, Shengdian Wang, Masao Ichikawa, Cecilia Rietz, Dallas B. Flies, Julie S. Lau, Gefeng Zhu, Koji Tamada, Lieping Chen - Cancer Research 2005 被引用: 1,004

  7. Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

    著者: Koji Tamada, Degui Geng, Yukimi Sakoda, Navneeta Bansal, Ratika Srivastava, Zhaoyang Li, Eduardo Dávila - Clinical Cancer Research 2012 被引用: 263

  8. B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity

    著者: Gabriel Sica, In-Hak Choi, Gefeng Zhu, Koji Tamada, Sheng-Dian Wang, Hideto Tamura, Andrei I. Chapoval, Dallas B. Flies, Jürgen Bajorath, Lieping Chen - Immunity 2003 被引用: 696

  9. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models

    著者: Shunsuke Goto, Yukimi Sakoda, Keishi Adachi, Yoshitaka Sekido, Seiji Yano, Masatoshi Eto, Koji Tamada - Cancer Immunology Immunotherapy 2021 被引用: 60

  10. Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells

    著者: Tatsuki Ueda, A Kumagai, Shoichi Iriguchi, Yutaka Yasui, T. MIYASAKA, Kengo Nakagoshi, Kazuki Nakane, Keigo Saito, Mari Takahashi, Aki Sasaki, Shinsuke Yoshida, Naoko Takasu, Hiroshi Seno, Yasushi Uemura, Koji Tamada, Tetsuya Nakatsura, Shin Kaneko - Cancer Science 2020 被引用: 116

  11. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma

    著者: Yusuke Shinchi, Shiho Ishizuka, Yoshihiro Komohara, Eri Matsubara, Remi Mito, Cheng Pan, Daiki Yoshii, Kimihiro Yonemitsu, Yukio Fujiwara, Koei Ikeda, Koji Tamada, Takuro Sakagami, Makoto Suzuki - Cancer Immunology Immunotherapy 2022 被引用: 51

  12. Therapeutic effects of anti‐GM2 CAR‐T cells expressing IL‐7 and CCL19 for GM2‐positive solid cancer in xenograft model

    著者: Takahiro Sasaki, Yukimi Sakoda, Keishi Adachi, Yoshihiro Tokunaga, Koji Tamada - Cancer Medicine 2023 被引用: 25

  13. PD-1 on dendritic cells impedes innate immunity against bacterial infection

    著者: Sheng Yao, Shengdian Wang, Yuwen Zhu, Liqun Luo, Gefeng Zhu, Sarah J. Flies, Haiying Xu, William Ruff, Megan Broadwater, In-Hak Choi, Koji Tamada, Lieping Chen - Blood 2009 被引用: 204

  14. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer

    著者: Kimihiro Yonemitsu, Cheng Pan, Yukio Fujiwara, Yuko Miyasato, Takuya Shiota, Hiromu Yano, Seiji Hosaka, Koji Tamada, Yutaka Yamamoto, Yoshihiro Komohara - Scientific Reports 2022 被引用: 36

  15. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

    著者: Scott E. Strome, Haidong Dong, Hideto Tamura, Stephen G. Voss, Dallas B. Flies, Koji Tamada, Diva R. Salomão, John C. Cheville, Fumiya Hirano, Wei Lin, Jan L. Kasperbauer, Karla V. Ballman, Lieping Chen - 2003 被引用: 492

  16. Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

    著者: Stephen R. Goding, Kyle Wilson, Ying Xie, Kristina M. Harris, Aparna B. Baxi, Akgül Akpınarlı, Amy M. Fulton, Koji Tamada, Scott E. Strome, Paul A. Antony - The Journal of Immunology 2013 被引用: 209

  17. Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model

    著者: Jun‐ich Mori, Keishi Adachi, Yukimi Sakoda, Takahiro Sasaki, Shunsuke Goto, Hiroaki Matsumoto, Yoji Nagashima, Hideyasu Matsuyama, Koji Tamada - Cancer Science 2021 被引用: 37

  18. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance

    著者: Jang‐June Park, Ryusuke Omiya, Yumiko Matsumura, Yukimi Sakoda, Atsuo Kuramasu, Mathew M. Augustine, Sheng Yao, Fumihiko Tsushima, Hidehiko Narazaki, Sudarshan Anand, Yingjia Liu, Scott E. Strome, Lieping Chen, Koji Tamada - Blood 2010 被引用: 322

  19. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy

    著者: Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew S. Flies, Sarah J. Flies, Haiying Xu, Koji Tamada, Drew M. Pardoll, Lieping Chen - Blood 2007 被引用: 238

  20. Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors.

    著者: Takako Eguchi Nakajima, Yasutoshi Kuboki, Masaru Fukahori, Yutaka Shimazu, Shunsuke Kondo, Yuki Katsuya, Masafumi Ikeda, Tomoyuki Satake, Hideaki Kagehara, Takenori Akaike, Aman P. Singh, Kondala R. Atkuri, Petar Pop-Damkov, Koji Tamada, Takafumi Koyama - Journal of Clinical Oncology 2024 被引用: 15

  21. A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial

    著者: Masao Nakajima, Shoichi Hazama, Koji Tamada, Keiko Udaka, Yasunobu Kouki, Toshinari Uematsu, Hideki Arima, Akira Saito, Shun Doi, Hiroto Matsui, Yoshitaro Shindo, Satoshi Matsukuma, Shinsuke Kanekiyo, Yukio Tokumitsu, Shinobu Tomochika, Michihisa Iida, Shin Yoshida, Yuki Nakagami, Nobuaki Suzuki, Shigeru Takeda, Shigeru Yamamoto, Shigefumi Yoshino, Tomio Ueno, Hiroaki Nagano - Cancer Immunology Immunotherapy 2020 被引用: 23

  22. Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family

    著者: In-Hak Choi, Gefeng Zhu, Gabriel Sica, Scott E. Strome, John C. Cheville, Julie S. Lau, Yuwen Zhu, Dallas B. Flies, Koji Tamada, Lieping Chen - The Journal of Immunology 2003 被引用: 246

  23. Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1–Mediated Immune Suppression

    著者: Samuel Haile, Sonia P. Dalal, Virginia K. Clements, Koji Tamada, Suzanne Ostrand‐Rosenberg - The Journal of Immunology 2013 被引用: 81

  24. Improved survival of chimeric antigen receptor‐engineered T (CAR‐T) and tumor‐specific T cells caused by anti‐programmed cell death protein 1 single‐chain variable fragment‐producing CAR‐T cells

    著者: Masao Nakajima, Yukimi Sakoda, Keishi Adachi, Hiroaki Nagano, Koji Tamada - Cancer Science 2019 被引用: 53